BIO-key receives Nasdaq notice of non-compliance over delayed 10-Q filing
BIO-key International received a notice from Nasdaq on June 5, 2026, stating the company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, in violation of Nasdaq Listing Rule 5250(c)(1). The Nasdaq Hearing Panel will consider the non-compliance in determining the company's continued listing on the Nasdaq Capital Market. The company is appealing a May 6, 2026 Nasdaq determination to suspend trading and has a hearing scheduled for June 16, 2026.
Key facts
- Non-compliance notice received June 5, 2026 from Nasdaq Listings Qualifications Department
- Form 10-Q for period ended March 31, 2026 not timely filed
- Nasdaq Listing Rule 5250(c)(1) violation (Periodic Report Rule)
- Nasdaq Hearing Panel scheduled for June 16, 2026
- Trading suspension determination issued by Nasdaq May 6, 2026
- Company appealing May 6 suspension determination to Hearing Panel
Why it matters
The company faces potential delisting from Nasdaq Capital Market if it cannot regain compliance with periodic reporting requirements before the June 16 hearing; the filing deadline delay has triggered a formal delisting consideration process with no assurance of approval for continued listing.
Developing story
- NT 10-Q
- NT 10-K
- 8-Kthis filing
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-10. Not investment advice. View the source filing on SEC.gov →